Ticagrelor Pharma Grade API is a direct-acting, reversibly binding P2Y12 platelet ADP receptor antagonist supplied as a white to off-white crystalline powder with the molecular formula C₂₃H₂₈F₂N₆O₄S, molecular weight 522.57 g/mol, and CAS registry number 274693-27-5. The material is released under two grade designations: oral grade for tablet, capsule, and granule manufacturing, and injectable grade for parenteral formulation development. Because a harmonized public monograph for Ticagrelor is not universally adopted, the certificate of analysis is built around an in-house specification aligned with ICH Q6A, ICH Q3A, ICH Q3C, ICH Q3D, and ICH M7. Identity is established by X-ray powder diffractometry against the approved polymorphic reference pattern and by Fourier-transform infrared spectroscopy. The HPLC assay with ultraviolet detection uses a validated method; representative release criterion for oral material is 98.0–102.0% on the anhydrous and solvent-free basis, though the binding value is the approved dossier specification for the specific source. Related substances are controlled with reporting, identification, and qualification thresholds derived from ICH Q3A; a typical unspecified impurity limit is 0.10%, and total impurities are typically controlled at 0.5%. Residual solvents are determined by headspace gas chromatography according to USP <467>, and residual palladium from catalytic hydrogenation is controlled at not more than 10 ppm, with the final elemental impurity limit expressed according to the maximum daily dose under ICH Q3D. Sulfated ash is tested according to USP <281>, loss on drying at not more than 0.5%, and water content by Karl Fischer titration unless otherwise specified. The particle-size distribution is measured by laser diffraction; micronized oral grades are commonly controlled at D90 ≤ 20 µm, but the exact target is process-specific and must be agreed between the API manufacturer and the dosage-form developer because Ticagrelor is dissolution-limited and batch-to-batch particle-size shifts can propagate into dissolution and content uniformity variation.

What Distinguishes Ticagrelor from Prodrug-Based P2Y12 Inhibitors?

Ticagrelor is not a thienopyridine prodrug. Unlike clopidogrel bisulfate and prasugrel hydrochloride, which require metabolic activation to generate a thiol active metabolite that binds irreversibly to the P2Y12 receptor, Ticagrelor itself binds directly and reversibly. Its primary active metabolite, AR-C124910XX, is formed via CYP3A4-mediated biotransformation and also exhibits P2Y12 antagonist activity. The parent elimination half-life is in the range of 7–9 h, and the metabolite half-life is approximately 9–12 h; by comparison, the active thiol metabolites of clopidogrel and prasugrel have elimination half-lives of approximately 0.5 h. These pharmacokinetic differences are relevant to the clinical performance of the finished dosage form but do not replace the need for formulation-specific dissolution and stability data. From an API release perspective, Ticagrelor does not require the same thiophene-related activation pathway, and the impurity profile is therefore dominated by process impurities and degradants from the triazolopyrimidine synthetic route. The comparative table summarizes the major differentiating features.

For tablet and capsule manufacturing, the oral grade of Ticagrelor is normally micronized to increase the specific surface area available for dissolution. The micronized powder exhibits high cohesiveness; therefore, dry premixing in a bin blender or high-shear mixer with a hydrophilic filler such as mannitol or dibasic calcium phosphate anhydrous is used before lubrication with magnesium stearate. Extended blending after lubrication is avoided because over-lubrication can retard dissolution through hydrophobic surface coverage. Granule formation by wet granulation is used when improved flow and reduced segregation are required. In a high-shear granulator, the impeller tip speed, water addition rate, and wet massing time are critical processing parameters; overgranulation can produce dense granules with slow disintegration. Drying in a fluid-bed dryer is controlled by inlet air temperature and product temperature, and the endpoint is set by loss on drying. After drying and milling through a conical mill, X-ray powder diffractometry is performed to confirm that the crystalline form has not changed. The granule size distribution is measured by sieve analysis according to USP <786>, and powder flow is characterized by bulk density, tapped density, Carr index, and angle of repose according to USP <616> and USP <1174>. Tablet compression is monitored for hardness according to USP <1217>, friability according to USP <1216>, and disintegration according to USP <701>. Dissolution testing is conducted with USP <711> apparatus 2 or apparatus 1; because Ticagrelor is reported as BCS Class IV, dissolution media without surfactant may provide inadequate sink conditions and may not be discriminative. The choice of surfactant type and concentration is file-specific and is established during method development rather than taken from a general monograph.

Capsule filling with Ticagrelor granules or powder blends is carried out on dosator or tamping-pin capsule fillers. The flow requirement is more stringent for tamping-pin machines because the powder bed must be uniformly densified; a Carr index below 25% is generally preferred, but the exact acceptance range depends on the filler model and line speed. Tamping-pin force and pin depth affect fill weight variability, particularly at low fill weights. Content uniformity is tested according to USP <905>; if the API is present below 25 mg per dosage unit, the blend potency and particle-size distribution become critical process parameters. Batch-to-batch variance in Ticagrelor particle size is controlled because dissolution clearance is limited and changes in the surface area can shift the in vitro release profile.

When a Micronized Ticagrelor Blend Reaches a High-Speed Rotary Press

On a high-speed rotary tablet press, feed-frame paddle speed, die table speed, and compression force are interconnected. If the powder blend has poor flow, the feed frame may not fill dies uniformly; this risk is elevated with micronized Ticagrelor because the API is cohesive. A glidant such as colloidal silicon dioxide is often included at 0.1–0.5% w/w, but the level is optimized because excessive glidant can interfere with wetting and dissolution. Compression profiles are evaluated through compactability, compressibility, and tabletability plots; punch sticking and picking are monitored with tooling condition and environmental humidity as controlled variables. Precompression force and main compression force are set to achieve target tablet hardness without causing capping or lamination. Tablet rejection limits for weight, thickness, and hardness are established during process validation and tied to dissolution data. Feed-frame speed is adjusted to prevent segregation of Ticagrelor from high-density diluents such as calcium phosphate; segregation risk increases when the API and diluent particle-size distributions are poorly matched. If direct compression is not robust, the process is converted to roller compaction or wet granulation to lock the particle-size distribution before final compression.

Injectable-Grade API and the Aqueous Solubility Constraint

Injectable dosage development with Ticagrelor API is limited primarily by aqueous solubility. The neutral molecule has low intrinsic solubility in water and pH-dependent ionization due to basic nitrogen centers; a simple ready-to-use aqueous injection at neutral pH is not practical without a solubilization strategy. Published data for a specific parenteral Ticagrelor formulation is limited, so development work must establish the solubility profile in the selected vehicle across the pH range. Injectable-grade material is released with additional microbiological and particulate controls because the final product may be sterilized by filtration or aseptically processed. The API must meet the endotoxin limit and sub-visible particulate matter requirements shown in the release panel. For formulation, acidic vehicles may increase solubility through protonation, but the chemical stability of the drug in acidic solution is confirmed by HPLC under stress conditions aligned with ICH Q1A. Alternative approaches such as cyclodextrin inclusion or nanosuspension may be considered, but filterability and particle-size stability in the colloidal system are evaluated. The API supplier provides data for the injectable grade on elemental impurities per ICH Q3D, residual solvents, and the absence of bacterial endotoxins. Terminal sterilization is evaluated only after confirming that the drug and vehicle remain within specification; the limiting factors are usually the vehicle and container closure system rather than the API alone. Sterile API is not a recognized substitution for aseptic formulation; injectable manufacturing requires the same environmental controls and process simulations as other parenteral drugs. If a suspension injection is developed, particle-size distribution and dissolution at the intended injection site are critical quality attributes that are controlled through the final product specification.

Compared with clopidogrel bisulfate and prasugrel hydrochloride, Ticagrelor API carries a higher molecular weight and lower aqueous solubility, which changes the solid-dosage process risk profile. The commercial API is supplied as the neutral parent molecule rather than a simple acid addition salt. This means salt selection is not available as a solubility enhancer for the commercial form. Blending and granulation with Ticagrelor should avoid strongly alkaline fillers unless compatibility is confirmed; the sulfonamide and triazole functional groups may be susceptible to hydrolytic or oxidative degradation under extreme conditions. Compatibility with common excipients is confirmed by forced degradation and binary mixture studies under ICH Q1A. Because Ticagrelor is dissolution-limited, any change in particle-size distribution between API batches or from a change in micronization site is evaluated for impact on dissolution and content uniformity. Published data for specific process configurations is limited; therefore, process validation includes end-to-end evaluation from API particle-size distribution to final tablet dissolution. In high-speed direct compression, the feed-frame speed and paddle speed may require adjustment based on powder flow; segregation risk increases when Ticagrelor is blended with high-density diluents. This is controlled by matching particle-size distributions or by granulating the blend. If the product is manufactured as a granule, the final granule is filled into sachets or compressed into tablets; granule moisture content is kept low, and storage above 60% RH is avoided unless the packaging provides a sufficient moisture barrier. Incompatibilities with strong oxidizing agents are considered in cleaning validation; equipment surfaces are cleaned with a validated process because the low aqueous solubility of Ticagrelor may make it difficult to remove from contact surfaces without a solvent or alkaline detergent.